IMPACT OF PHARMACOKINETICS ON THE RISK ASSESSMENT OF DICHLOROMETHANE
Notice - This site contains archived material(s)
Archive disclaimer
Archive
disclaimer
Archived files are provided for reference
purposes only. These files are no longer maintained by the Agency and may be outdated. For
current EPA information, go to www.epa.gov. It is EPA's policy to
support reasonable accommodation to persons with disabilities, pursuant to the Rehabilitation
Act of 1973, 29 U.S.C. 791. If you need assistance with accessing archived files, contact
EPA's Reasonable Accommodations
or submit a request using the Contact Us form.
Abstract
The paper recapitulates the means by which a physiologically based risk assessment for dichloromethane (DCM, methylene chloride) evolved. Two somewhat different physiologically based pharmacokinetic (PBPK) models had been published by Angelo et al. in 1984 and Andersen et al. in 1987. The paper discusses the rationale for the selection and implementation of a PBPK model for purposes of estimating the delivered or effective dose. Also discussed is the rationale used for selecting the scaling method for estimating the equivalency of delivered dose between test species and humans.
Citation
Blancato, J. AND L. Rhomberg. IMPACT OF PHARMACOKINETICS ON THE RISK ASSESSMENT OF DICHLOROMETHANE. U.S. Environmental Protection Agency, Washington, D.C., EPA/600/D-88/219 (NTIS PB89173249), 1988.